Aalberts Is Paying 46% More to Buy Its Own Shares Than in April — the Buyback Shows the Cheap Window Has Closed

Aalberts' weekly buyback notices are the kind of press release most investors delete on sight: a few thousand shares, a few million euros, the same boilerplate. But read the prices across the year and one line stands out. This morning's notice, covering the 24–28 August week, says the Dutch industrial company repurchased 70,000 of its own shares for €3,029,010.60, at an average of €43.27 each. In the first week of April, the same programme was paying €29.71 a share. Same company, same €75 million authorised in February, execution price roughly 46% higher in five months.

The programme is a fixed amount of cash, not a fixed number of shares. That is the detail worth understanding, because it means the buyback has been doing a different amount of mechanical work at different times. At €30, €75 million cancels about 2.5 million shares. At €43, the same money cancels about 1.7 million. By the end of August the company had spent €54.9 million of its €75 million and retired just over 1.59 million shares — a little under 1.5% of the roughly 107 million shares outstanding, with the balance due by the 9 October deadline. Shares repurchased are cancelled, so the reduction is permanent rather than treasury stock.

What justified the higher price

The obvious reaction is that management paid up for its own stock, and did so just as the market was re-rating it. That is true and it matters, but the price is only foolish if the business no longer supports it. Look at what happened to earnings between February and August.

Full-year 2025 was the down year that made the shares cheap: revenue of €3,091 million, organic sales down 2.5%, EBITA of €410 million at a 13.2% margin, with management citing soft end markets, macroeconomic uncertainty and geopolitical disruption. Earnings per share before amortisation were €2.61. Against that stack, a €29.71 share price was 11.4 times earnings before amortisation — the kind of multiple a beaten-down, temporarily unloved compounder produces at a trough.

The first half of 2026 reversed the story. Organic revenue grew 5.0% on €1,560 million of sales, EBITA rose 7% to €225.2 million — slightly ahead of consensus — and the margin expanded 90 basis points to 14.4%. Momentum accelerated through the period, with second-quarter EBITA up 11% versus 4% in the first quarter. The semicon segment, added as a separate reporting line under the "thrive 2030" strategy, was the standout: EBITA up 88%, margin 14.2%, on a 9.2% organic advance and an AI-driven order book the company calls very strong. Management cited positive dynamics in data centres, aerospace, power generation and defence, with automotive and residential building stable, and guided to improved full-year organic growth and margin. Aalberts entered the second half near the top of its 52-week range.

That is the mechanism the buyback notices obscured: the €30→€43 move was not a speculative re-rating on sentiment; it was the market capitalising a margin and growth recovery the company itself was affirming through a higher cash bid for its own shares.

Who pays for the buyback

The first test for any repurchase is whether it is funded by real cash flow or by a balance sheet that cannot afford it — and here the evidence is unambiguous. Free cash flow was €361 million in 2025 and €88.6 million in the first half of 2026 alone, up 57%. A full year of total cash return — the €1.15 per share dividend, roughly €125 million at the current share count, plus the €75 million buyback — runs to about €200 million, barely more than half of last year's free cash flow. The balance sheet is not stressed to do it: solvency stood at 56.1% at the end of 2025, equity is roughly €2.4 billion, and although the H1 acquisitions pushed net debt to about 1.9 times EBITDA from 1.6 times, nothing about the leverage constrains a €75 million programme. The buyback is not competing with the dividend, with reinvestment, or with bolt-on deals. It is spare cash being handed back, and the dividend itself is comfortably covered at a 44% payout of earnings before amortisation.

The dividend is the other half of the return story. The €1.15 per share proposed for 2025, paid in May, is a small step up from the €1.13 of the prior two years, and the yield is about 2.7% at today's price. Aalberts has now been raising or holding its payout for a decade, which is precisely the kind of income-and-compounder profile that belongs in a value sleeve — but the yield was meaningfully larger in the €30s than it is at €43.

What the notices no longer tell you

At €43.27, the stock trades at roughly 16.6 times the €2.61 of earnings per share before amortisation it earned in 2025. That is still below the multiple a quality niche industrial used to command, and if the first-half momentum holds — H1 EBITA of €225 million already exceeds half of last year's full-year €410 million, and the second half is normally the stronger one — earnings per share should move above last year's figure, pushing the multiple into the mid-teens. That is a fair, not a bargain, price for a recovering compounder with a fortress balance sheet and a genuine growth engine in semicon.

The honest reading of this week's notice is that it is a record of what already happened, not a fresh signal. The value gap was open in February through April, when the buyback was buying at roughly €30 against €2.61 of earnings carry, and management kept buying while the market still doubted the recovery. That is the discipline a value investor is supposed to copy: buy the durable cash flow when the label is temporarily ugly. By August, the market had caught up. New money at €43 is backing the same company at a normalised price, with the risk that the recovery is already in the multiple.

The weekly notices will not tell you when Aalberts is cheap again; they only confirm that the payout can be funded, which was never the question. The question is whether 14% margins and mid-single-digit organic growth persist into 2027. If they do, today's price is acceptable for a compounder in a diversified income-and-value portfolio. If they roll over, the buyback prices worth watching — the €29 and €44 tranches the company itself paid — mark the range the market has already established.